文献速递核素与放射性配体治疗肿瘤 PET/CT

18F-FAPI PET/CT与基于体素的肿瘤吸收剂量对90Y树脂微球SIRT治疗不可切除肝细胞癌反应及临床结局的预测价值

The predictive value of 18F-FAPI PET/CT and voxel-based tumor absorbed dose for the response and clinical outcome of unresectable hepatocellular carcinoma patients treated with Yttrium-90 resin microsphere selective internal radiation therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-10

该前瞻性研究纳入43例不可切除肝细胞癌患者,比较SIRT前18F-FAPI与18F-FDG PET/CT参数及SIRT后基于体素的肿瘤吸收剂量对3个月靶病灶反应和生存的预测价值。短期靶病灶反应率为60.5%,较高的SIRT前FTV-target和TLF-target是短期反应的独立预测因素,较高的FTV-WB/TLF-WB预测更差PFS但非独立,SIRT后单药治疗、较高AFP及较低Dmean/D50是PFS的独立预后因素。

要点

  • SIRT前18F-FAPI PET/CT的FTV-target和TLF-target可独立预测uHCC患者3个月靶病灶反应。
  • SIRT后基于体素的Dmean和D50较低与更差PFS独立相关。
  • 18F-FAPI PET/CT可能有助于SIRT前uHCC患者筛选。

核心结论

  • SIRT前FAPI-avid体积参数除肿瘤吸收剂量外,对uHCC患者SIRT后短期靶病灶反应具有潜在预测价值。
  • 18F-FAPI PET/CT可能有助于SIRT前uHCC患者筛选。

研究设计与样本

  • 前瞻性招募接受SIRT前18F-FDG和18F-FAPI PET/CT的uHCC患者。
  • 共纳入43例uHCC患者,平均年龄51.0±10.2岁,88.4%为男性。
  • 从18F-FDG PET/CT获取MTV-target/MTV-WB和TLG-target/TLG-WB,从18F-FAPI PET/CT获取FTV-target/FTV-WB和TLF-target/TLF-WB。
  • 从SIRT后PET/CT计算靶病灶基于体素的肿瘤吸收剂量参数,包括Dmean、D50、D75和D90。
  • 短期(3个月)靶病灶反应采用mRECIST 1.1标准评估,主要终点为短期TLR和PFS,次要终点为OS。

主要发现

  • 短期TLR率为60.5%(26/43),疾病控制率为88.4%。
  • TLR组MTV-target、TLG-target、FTV-target和TLF-target显著低于NTLR组,Dmean/D50/D75呈相似趋势。
  • 较高的SIRT前FTV-target(>303.5 cm³)和TLF-target(>1129.1)是短期反应的独立预测因素(OR=6.33,95%CI:1.43–28.00,P=0.015)。
  • 中位PFS为6.6个月(95%CI:4.4–10.5),中位OS为13.1个月(95%CI:10.5–未达到)。
  • 较高的FTV-WB(>333.9 cm³)/TLF-WB(>1256.1)预测更差PFS,但非独立预测因素。

关键数值与推荐

  • 短期靶病灶反应采用mRECIST 1.1标准评估。
  • SIRT后单药治疗是PFS的独立预后因素(HR=3.27,95%CI:1.18–9.06,P=0.023)。
  • 较高甲胎蛋白(>343.1 ng/mL)是PFS的独立预后因素(HR=3.25,95%CI:1.84–8.90,P=0.022)。
  • 较低Dmean(≤151 Gy)/D50(≤142 Gy)是PFS的独立预后因素(HR=2.64,95%CI:1.07–6.55,P=0.036)。

临床怎么用

  • SIRT前可考虑行18F-FAPI PET/CT,利用FTV-target和TLF-target辅助筛选可能从SIRT获益的uHCC患者。
  • SIRT后基于体素的肿瘤吸收剂量参数Dmean和D50可用于预后分层,较低Dmean(≤151 Gy)或D50(≤142 Gy)提示更差PFS。
  • 结合甲胎蛋白水平和是否联合SIRT后单药治疗等临床因素综合评估PFS预后。

局限性

  • 研究样本量较小,共43例患者。
  • 试验为回顾性注册(ChiCTR2500107817,注册日期2025年8月19日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fibroblast activation protein (FAP) may contribute to radiotherapy resistance. This study aimed to compare baseline 18F-labeled fibroblast activation protein inhibitor (18F-FAPI) PET/CT and 18F-FDG PET/CT in short-term target lesion response (TLR) and clinical outcome prediction in unresectable hepatocellular carcinoma (uHCC) patients treated with Yttrium-90(90Y) resin microsphere selective internal radiation therapy (SIRT). METHODS: Patients with uHCC undergoing pre-SIRT 18F-FDG and 18F-FAPI PET/CT were prospectively recruited. Semiquantitative parameters, including target/whole-body metabolic tumor volume (MTV-target/MTV-WB) and total lesion glycolysis (TLG-target/TLG-WB), were obtained from 18F-FDG PET/CT, while target/whole-body FAPI-avid tumor volume (FTV-target/FTV-WB) and total lesion FAP expression (TLF-target/TLF-WB) were derived from 18F-FAPI PET/CT. Voxel-based tumor absorbed dose(TAD) parameters for target lesions were calculated from post-SIRT PET/CT, including the mean TAD (Dmean) and TAD to 50%, 75%, and 90% of the tumor volume (D50, D75, D90). Short-term (3-month) target lesion response was assessed by mRECIST 1.1 criteria. Primary endpoints were short-term TLR and progression-free survival (PFS). The secondary endpoint was overall survival (OS). RESULTS: Forty-three uHCC patients (mean age 51.0 ± 10.2 years, 88.4% male) were included. The short-term TLR rate was 60.5% (26/43), with a control rate of 88.4%. The TLR group showed significantly lower MTV-target, TLG-target, FTV-target, and TLF-target than the non-target lesion response group (NTLR), with similar trends for Dmean/D50/D75. Higher pre-SIRT FTV-target (> 303.5 cm³) and TLF-target (> 1129.1) were independent predictors of short-term response [odds ratio = 6.33, 95% confidence interval (CI): 1.43–28.00, P = 0.015]. Median PFS was 6.6(95%CI:4.4–10.5) months, and median OS was 13.1(95%CI:10.5-not reached) months. Higher FTV-WB(> 333.9cm3)/TLF-WB (> 1256.1) predicted worse PFS, though not independently. Post-SIRT monotherapy [hazard ratio (HR) = 3.27, 95%CI:1.18–9.06, P = 0.023), higher alpha-fetoprotein (> 343.1ng/mL) (HR = 3.25, 95%CI:1.84–8.90, P = 0.022), and lower Dmean (≤ 151 Gy)/D50(≤ 142 Gy) (HR = 2.64, 95%CI:1.07–6.55, P = 0.036) were independent prognostic factors for PFS. CONCLUSION: Pre-SIRT FAPI-avid volumetric parameters demonstrated potential value for predicting short-term TLR in uHCC patients receiving SIRT, in addition to TAD. 18F-FAPI PET/CT may facilitate uHCC patient selection before SIRT. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2500107817), registered on 19 August 2025, retrospectively registered.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gong H, Cheng Y, Li Q, et al. The predictive value of 18F-FAPI PET/CT and voxel-based tumor absorbed dose for the response and clinical outcome of unresectable hepatocellular carcinoma patients treated with Yttrium-90 resin microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41518401. doi:10.1007/s00259-025-07717-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。